Evernote Releases v11, Marking a New Chapter in AI-Powered Productivity
19.1.2026 18:00:00 EET | Business Wire | Press release
Evernote today announced the release of v11, its first major product update in five years. The new version includes three powerful AI features—AI Assistant, Semantic Search, and AI Meeting Notes—creating smarter ways to capture, retrieve, and manage information in Evernote. With the release of v11, these features are now available to all Evernote customers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260119103272/en/
Two years of work culminating in a major update
V11 is a recognition of Evernote’s evolution under Bending Spoons’ stewardship. Since 2024, Evernote has released more than 250 new features and improvements while also greatly enhancing sync, speed, and reliability. With v11, Evernote ushers in an exciting new phase of development and innovation, bringing customers novel ways to engage with their preferred productivity tool.
“Evernote has been part of people’s lives for years, often decades. They’ve always inspired and shaped how our platform evolves,” said Federico Simionato, product lead at Evernote. “Through hundreds of interviews and workshops we designed v11’s AI features to make people’s everyday needs of capturing, organizing and retrieving information in Evernote more intuitive and efficient than ever.”
Powerful new AI features
V11’s three new AI features—AI Assistant, Semantic Search, and AI Meeting Notes—build directly on Evernote’s core workflows while remaining adaptive to each user’s unique way of working and thinking. Anyone can unlock more powerful note-taking, organization, and productivity, regardless of their previous experience using Evernote.
AI Assistant—developed in close collaboration with OpenAI—brings conversational intelligence directly into Evernote, enabling users to interact with their notes, tasks, and calendar through a dedicated chat interface. By helping people summarize content, surface relevant information, and search the web for insights, AI Assistant makes everyday workflows more productive.
Semantic Search introduces a long-requested new search experience. Now, it’s possible to use natural language queries to surface relevant notes and key details, without the need for exact keyword matching. As a result, users can access the necessary information in their accounts quickly and efficiently.
AI Meeting Notes records, transcribes, and summarizes in-person and online meetings directly within Evernote, with support for multiple speakers. By capturing conversations accurately and generating summaries with key action items, AI Meeting Notes help users stay focused during meetings and make it easy to revisit important information afterwards.
To give users greater control over their experience, individual AI features can be enabled or disabled via new settings. As of release, AI Assistant is available on Evernote Desktop and Web only, while Semantic Search and AI Meeting Notes are available on Desktop, Web, and Mobile.
Read more about v11’s AI features at evernote.com.
Building the future of Evernote beyond AI
In addition to new AI capabilities, v11 includes improvements to the core functions of Evernote, including note editing, capture, and navigation. With v11, Evernote also introduces a refreshed Evernote brand identity, including an updated logo and a modernized visual language. The new design reflects the evolution of the brand while preserving its core identity.
V11 is rolling out to all Evernote users starting January 19, 2026.
About Evernote
Evernote is the leading productivity app designed to help people capture, organize, and act on their ideas. Used by millions worldwide, Evernote brings notes, tasks, documents, and schedules together in one flexible workspace, making it easier to stay focused and productive across devices.
Learn more at evernote.com.
About Bending Spoons
Bending Spoons acquires and transforms digital businesses. It owns Brightcove, Evernote, komoot, Meetup, Remini, StreamYard, WeTransfer, Vimeo and many others. The company’s products have served more than a billion people, with over 400 million monthly active users and 10 million paying customers, including most Fortune 500 enterprises. Learn more at bendingspoons.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260119103272/en/
Contacts
Media contacts
Evernote:
Rebecca Shamritsky
rebs@bendingspoons.com
Bending Spoons:
Christy Keenan
ck@bendingspoons.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Codethink Opens Early Access to IEC 61508 Mapping for the Eclipse Trustable Software Framework11.3.2026 09:07:00 EET | Press release
EMBEDDED WORLD--Codethink today opened early access to its mapping between the Eclipse Trustable Software Framework (TSF) and IEC 61508, the international standard governing the functional safety of electrical and electronic systems. The mapping establishes a transparent relationship between the engineering principles of the Trustable Software Framework and the objectives defined in IEC 61508. By making this work available as an early preview, Codethink is inviting organisations interested in applying open source approaches to functional safety to review and begin working with the mapping while the work continues to mature. IEC 61508 forms the foundation of many domain-specific safety standards, including ISO 26262 for automotive systems. The early access reflects Codethink’s long-standing commitment to open development of software engineering methods. “This preview release reflects our belief that trust in software must be engineered in the open," said Paul Sherwood, Codethink’s Chair
FERM FOOD Acquires Orkla’s Former Site and Scales Up: Up to 20,000 Tonnes of Fermented Ingredients Per Year11.3.2026 08:00:00 EET | Press release
Danish ingredient producer FERM FOOD is acquiring Orkla’s former manufacturing site in Skovlund, Denmark, effective 1 April 2026. The acquisition provides new production facilities to expand the output of fermented plant-based ingredients for the food industry — driven by export demand that has emerged faster than expected. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310904877/en/ Jens Legarth (CEO), Rikke Matthiesen (CSO), and Torbjørn Tyndkjær-Thomsen (Food & Process Developer) at FERM FOOD’s new production facilities. “We have outgrown our current facilities. With the Skovlund site, we can supply many more food manufacturers in Denmark and abroad. Global interest has developed faster than we expected — and that is why we are scaling up now,” says Jens Legarth, CEO of FERM FOOD. Once fully ramped up, the new fermentation facility is expected to reach an annual capacity of up to 20,000 tonnes, depending on product mix
Galderma Buys Back Shares Worth CHF 232 Million in the Context of Accelerated Bookbuild Offering11.3.2026 08:00:00 EET | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it has agreed to repurchase 1.6 million shares at a price of CHF 143.75 per share for a total consideration of CHF 232 million in the context of the accelerated bookbuild offering (“ABO”) of Galderma shares by Sunshine SwissCo GmbH (“EQT”), Abu Dhabi Investment Authority (Private Equities Department) and Auba Investment Pte. Ltd. (all together the “Selling Shareholders”) launched yesterday evening. The repurchase was made at the same price per share determined by the bookbuilding offering. As a result of yesterday evening’s ABO, the Selling Shareholders have fully divested their remaining stake in Galderma. The repurchase, which is expected to settle on March 13 is being financed by Galderma’s existing liquidity on hand and will not affect the company’s ability to deliver on its strategic and financing priorities. The shares will be held in treasury for future use in connection with Galderma's employe
Thales Launches SkyDefender: The Integral Air and Missile Defence Dome With Artificial Intelligence11.3.2026 08:00:00 EET | Press release
As air and missile threats are evolving faster than ever, from slow-moving drones to hypersonic missiles, attacks are becoming increasingly complex, saturating and unpredictable. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310398606/en/ SkyDefender © Thales Thales SkyDefender provides full protection against all types of air threats, from a few kilometres to several thousands of kilometres: Short-range: for protection of forces, vital assets and sensitive sites: ForceShield creates a real protection bubble against lower layer and surface threats at very short- and short-range, such as drones. Medium-range: for protection at theatre-level defence: SAMP-T NG by eurosam1 with up to 150 km engagement range, including Thales’ powerful Ground Fire radar with 350 km range and 360°/90° coverage against medium-range defence. Long-range: for protection against long-range threats with early-warning capabilities: a unique capacity
Curatis and Neupharma Announce Exclusive Licensing Agreement to Develop and Market Corticorelin (C-PTBE-01) for the Treatment of Peritumoral Brain Edema in Japan11.3.2026 08:00:00 EET | Press release
Curatis Holding AG (SIX: CURN) and Neupharma Co., Ltd. (“Neupharma”), a Japanese pharmaceutical company specializing in oncology, immunology, pulmonology and cardiology disorders, today announce an exclusive license and development agreement for corticorelin (C-PTBE-01) in Japan. Under the terms of the agreement, Neupharma will receive exclusive rights to develop and commercialize corticorelin for the treatment of peritumoral brain edema (PTBE) in Japan. PTBE is a tumor-associated condition for which no approved targeted therapies currently exist. Neupharma will finance and conduct a pivotal clinical trial in Japan to support filing for approval in Japan. Curatis will receive upfront and milestone payments for the achievement of regulatory and commercial targets totaling up to CHF 83.5 million, as well as royalties on future sales in Japan of up to 20%. The agreement stipulates that corticorelin is planned to be introduced in Japan initially for children and adolescents. A meeting with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom